+290.9%
MRVL vs GSK
+47.3%
+243.6%
-61.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.3% | +0.2% | +4.1% | +4.2% |
| 7D | +13.8% | -3.6% | +17.4% | +14.0% |
| 30D | +12.7% | -5.9% | +18.6% | +13.0% |
| 3M | -11.9% | -4.3% | -7.7% | -11.9% |
| 6M | +153.8% | -10.8% | +164.6% | +155.8% |
| YTD | +177.0% | +1.8% | +175.2% | +175.1% |
| 1Y | +252.3% | +23.5% | +228.9% | +241.9% |
| 3Y | +325.5% | +49.5% | +276.0% | +289.8% |
| 5Y | +290.9% | +49.7% | +241.2% | +259.4% |
| All | +290.9% | +47.3% | +243.6% | +259.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling